Ruxolitinib in CMML: A case study of innovative trial design in a rare cancer

Aditi Shastri, Diego A. Adrianzen-Herrera

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients.

Original languageEnglish (US)
Pages (from-to)6069-6071
Number of pages3
JournalClinical Cancer Research
Volume27
Issue number22
DOIs
StatePublished - Nov 15 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Ruxolitinib in CMML: A case study of innovative trial design in a rare cancer'. Together they form a unique fingerprint.

Cite this